We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
Webinar

Utilizing the Gibco™ CTS™ Rotea™ System, a Versatile Closed Manufacturing System, for Cell and Gene Therapy Development

Rectangle Image
Webinar

Utilizing the Gibco™ CTS™ Rotea™ System, a Versatile Closed Manufacturing System, for Cell and Gene Therapy Development

Mary Ann Santos
Mary Ann Santos
Cell and Gene Therapy Senior Business Development Manager
Emily Benz
Emily Benz
Process Development Engineer II, ViaCyte
Eric Dubofsky
Eric Dubofsky
Biomedical Engineering Master's student at Cal Poly San Luis Obispo

Cell and gene therapy involves extracting cells, protein or genetic material from a patient or donor and altering them to provide a highly personalised therapy. These therapies have shown potential to offer longer-lasting effects than traditional methods.


In this talk, we will discuss the value of moving towards modular and automated, closed-system technologies designed to enable scalable and cost-effective manufacturing. Also learn more about how ViaCyte, a clinical stage regenerative medicine company, is focused on delivering novel stem cell-derived pancreatic cell replacement therapies as a functional cure for diabetes. Producing the stem cells required to support development of these therapies and future commercial demand requires an aggressive scale-up effort.


Watch this webinar to learn about:

The current challenges in cell therapy manufacturing 

How the Gibco CTS Rotea system utilizes the proven counterflow centrifugation method to enable exceptional performance for cell therapy development

How the Rotea system is processing stem cell aggregates in bioreactors as part of a cell therapy scale-up effort

Advertisement